Grifols SA
$
20.12
0.08 (0.4%)
| Volume: | 1,046,075 | Avg Vol (1m): | 977,208 |
| Market Cap $: | 17.26 Bil | Enterprise Value $: | 17.32 Bil |
| P/E (TTM): | 30.30 | P/B: | 3.87 |
| Earnings Power Value | 9.56 |
| Net Current Asset Value | -6.5 |
| Tangible Book | -3.57 |
| Projected FCF | 9.46 |
| Median P/S Value | 19.95 |
| Graham Number | 0 |
| Peter Lynch Value | 4.36 |
| DCF (FCF Based) | 1.81 |
| DCF (Earnings Based) | 14.51 |
1Y (-%)
Manual of Stocks™ Web
Financial Strength : 6/10
GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| Current | vs industry | vs history | |
|---|---|---|---|
| Cash-to-Debt | 2.29 |
Cash-To-Debt ranked
lower than
100.00%
of
859
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 91151, Med: 2.03, Min: -0.01
GRFS:
2.29
Ranked among companies with meaningful Cash-To-Debt only.
|
Cash-To-Debt range over the past 10 years
Min: 0.03, Med: 0.18, Max: 10000
Current: 2.29
|
| Equity-to-Asset | 0.33 |
Equity-to-Asset ranked
lower than
79.06%
of
788
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 1.78, Med: 0.64, Min: -27.83
GRFS:
0.33
Ranked among companies with meaningful Equity-to-Asset only.
|
Equity-to-Asset range over the past 10 years
Min: 0.28, Med: 0.33, Max: 0.37
Current: 0.33
|
| Debt-to-Equity | 0.08 |
Debt-to-Equity ranked
lower than
75.34%
of
596
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 31.22, Med: 0.32, Min: 0.01
GRFS:
0.08
Ranked among companies with meaningful Debt-to-Equity only.
|
Debt-to-Equity range over the past 10 years
Min: 0.04, Med: 1.45, Max: 5.26
Current: 0.08
|
| Debt-to-EBITDA | 0.27 |
Debt-to-EBITDA ranked
higher than
66.67%
of
495
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 343059.67, Med: 1.92, Min: 0.01
GRFS:
0.27
Ranked among companies with meaningful Debt-to-EBITDA only.
|
Debt-to-EBITDA range over the past 10 years
Min: 0.27, Med: 4.29, Max: 8.67
Current: 0.27
|
| Interest Coverage | 3.28 |
Interest Coverage ranked
lower than
71.14%
of
648
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 2689668, Med: 86.08, Min: 0.01
GRFS:
3.28
Ranked among companies with meaningful Interest Coverage only.
|
Interest Coverage range over the past 10 years
Min: 1.63, Med: 4.07, Max: 18.16
Current: 3.28
|
| Piotroski F-Score | 4 |
0
1
2
3
4
5
6
7
8
9
| |
| Altman Z-Score | 1.87 |
DISTRESS
GREY
SAFE
| |
| Beneish M-Score | -1.99 |
Not Manipulator
Manipulator
| |
| WACC vs ROIC % |
ROIC 13.24%
WACC 3.39%
| ||
Profitability & Growth : 7/10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
| Current | vs industry | vs history | |
|---|---|---|---|
| Operating Margin % | 21.22 |
Operating Margin ranked
higher than
90.26%
of
801
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 8950, Med: 7.97, Min: -232970.37
GRFS:
21.22
Ranked among companies with meaningful Operating Margin only.
|
Operating Margin range over the past 10 years
Min: 15.53, Med: 23.94, Max: 26.85
Current: 21.22
|
| Net Margin % | 12.28 |
Net Margin ranked
higher than
86.03%
of
802
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 304900, Med: 5.32, Min: -216285.19
GRFS:
12.28
Ranked among companies with meaningful Net Margin only.
|
Net Margin range over the past 10 years
Min: 2.8, Med: 13.39, Max: 16.2
Current: 12.28
|
| ROE % | 13.88 |
ROE ranked
higher than
86.18%
of
832
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 316.96, Med: 5.94, Min: -3119.47
GRFS:
13.88
Ranked among companies with meaningful ROE only.
|
ROE range over the past 10 years
Min: 4.27, Med: 17.62, Max: 28.28
Current: 13.88
|
| ROA % | 4.73 |
ROA ranked
higher than
80.83%
of
871
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 943.36, Med: 2.88, Min: -1851.14
GRFS:
4.73
Ranked among companies with meaningful ROA only.
|
ROA range over the past 10 years
Min: 1.34, Med: 5.97, Max: 10.43
Current: 4.73
|
| ROC (Joel Greenblatt) % | 30.02 |
ROC (Joel Greenblatt) ranked
higher than
85.85%
of
855
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 34233.33, Med: 11.23, Min: -2671900
GRFS:
30.02
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
|
ROC (Joel Greenblatt) range over the past 10 years
Min: 18.09, Med: 32.72, Max: 42.62
Current: 30.02
|
| 3-Year Total Revenue Growth Rate | 4.50 |
3-Year Revenue Growth Rate ranked
higher than
64.73%
of
689
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 291.9, Med: 5.8, Min: -100
GRFS:
4.4
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
|
3-Year Revenue Growth Rate range over the past 10 years
Min: -5.6, Med: 10.4, Max: 51.6
Current: 4.4
|
| 3-Year Total EBITDA Growth Rate | 3.60 |
3-Year EBITDA Growth Rate ranked
lower than
54.55%
of
704
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 299.6, Med: 7.3, Min: -343.2
GRFS:
3.6
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
|
3-Year EBITDA Growth Rate range over the past 10 years
Min: 3.6, Med: 12.5, Max: 39
Current: 3.6
|
| 3-Year EPS w/o NRI Growth Rate | 3.70 |
3-Year EPS w/o NRI Growth Rate ranked
higher than
51.28%
of
663
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 385.8, Med: 8.9, Min: -403.2
GRFS:
3.7
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
|
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: -13.8, Med: 16.2, Max: 62.8
Current: 3.7
|
» GRFS's 30-Y Financials
Financials (Next Earnings Date: 2019-07-26)
Guru Trades Click for details
Guru Trades in
SEC Filings
Gurus Latest Trades with NAS:GRFS
» Interactive Chart
Peter Lynch Chart
Business Description
| Industry | Drug Manufacturers » Drug Manufacturers - Major   NAICS : 325412 |
| Compare | TSE:4578 HKSE:01093 TSE:4151 SHSE:600436 TSE:4528 MIL:REC TSE:4503 BOM:500302 BOM:500087 SZSE:002422 TSE:4536 TSE:2784 TSE:9987 OTCPK:GWPRF ISX:KLBF SZSE:300146 SHSE:600867 SZSE:002399 NSE:TORNTPHARM XKRX:008930 |
| Traded in other countries | GRF.Austria G0FB.Germany GRFPN.Mexico GRF.P.Spain 0RDU.UK |
| Address | Avinguda de la Generalitat, 152-158, Parque empresarial Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174 |
| As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's bioscience business contributed 79% of sales in 2017. Grifols also has smaller segments including diagnostics, hospital supplies, and biosupplies. Diagnostics grew to almost 20% of revenue in 2014 with the acquisition of Novartis' diagnostics unit. | |
Ratios
| Current | vs industry | vs history | |
|---|---|---|---|
| PE Ratio (TTM) | 30.30 |
PE Ratio ranked
higher than
74.15%
of
557
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 1910, Med: 23.77, Min: 0.06
GRFS:
30.3
Ranked among companies with meaningful PE Ratio only.
|
PE Ratio range over the past 10 years
Min: 21.73, Med: 29.38, Max: 81.6
Current: 30.3
|
| Forward PE Ratio | 17.36 |
Forward P/E ranked
higher than
68.47%
of
111
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 322.58, Med: 21.6, Min: 5.03
GRFS:
17.36
Ranked among companies with meaningful Forward P/E only.
| N/A |
| PE Ratio without NRI | 30.30 |
PE without NRI ranked
higher than
74.64%
of
556
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 2125, Med: 24.2, Min: 0.06
GRFS:
30.3
Ranked among companies with meaningful PE without NRI only.
|
PE without NRI range over the past 10 years
Min: 21.73, Med: 29.38, Max: 81.6
Current: 30.3
|
| Price-to-Owner-Earnings | 98.59 |
Price-to-Owner-Earnings ranked
lower than
100.00%
of
324
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 3160, Med: 31.95, Min: 0.17
GRFS:
98.59
Ranked among companies with meaningful Price-to-Owner-Earnings only.
|
Price-to-Owner-Earnings range over the past 10 years
Min: 18.11, Med: 34.15, Max: 100.16
Current: 98.59
|
| PB Ratio | 3.87 |
PB Ratio ranked
lower than
60.32%
of
819
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 227.39, Med: 2.64, Min: 0.05
GRFS:
3.87
Ranked among companies with meaningful PB Ratio only.
|
PB Ratio range over the past 10 years
Min: 2.32, Med: 4.25, Max: 6.76
Current: 3.87
|
| PS Ratio | 3.69 |
PS Ratio ranked
higher than
61.81%
of
775
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 9105.26, Med: 3.1, Min: 0.03
GRFS:
3.69
Ranked among companies with meaningful PS Ratio only.
|
PS Ratio range over the past 10 years
Min: 1.95, Med: 3.66, Max: 12.85
Current: 3.69
|
| Price-to-Free-Cash-Flow | 119.44 |
Price-to-Free-Cash-Flow ranked
higher than
57.38%
of
298
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 3143.75, Med: 30.84, Min: 0.23
GRFS:
119.44
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
|
Price-to-Free-Cash-Flow range over the past 10 years
Min: 15.6, Med: 35.3, Max: 121.38
Current: 119.44
|
| Price-to-Operating-Cash-Flow | 36.11 |
Price-to-Operating-Cash-Flow ranked
higher than
58.16%
of
392
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 14229.87, Med: 22, Min: 0.23
GRFS:
36.11
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
|
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 11.02, Med: 20.25, Max: 169.33
Current: 36.11
|
| EV-to-EBIT | 15.31 |
EV-to-EBIT ranked
higher than
73.25%
of
572
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 1015380.11, Med: 17.85, Min: 0.13
GRFS:
15.31
Ranked among companies with meaningful EV-to-EBIT only.
|
EV-to-EBIT range over the past 10 years
Min: 14.1, Med: 19.5, Max: 45.1
Current: 15.31
|
| EV-to-EBITDA | 12.25 |
EV-to-EBITDA ranked
higher than
74.37%
of
597
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 341528.02, Med: 15.24, Min: 0.12
GRFS:
12.25
Ranked among companies with meaningful EV-to-EBITDA only.
|
EV-to-EBITDA range over the past 10 years
Min: 11.7, Med: 16, Max: 37.1
Current: 12.25
|
| EV-to-Revenue | 3.27 |
EV-to-Revenue ranked
higher than
68.93%
of
795
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 23858.8, Med: 3.24, Min: 0.03
GRFS:
3.27
Ranked among companies with meaningful EV-to-Revenue only.
|
EV-to-Revenue range over the past 10 years
Min: 3.3, Med: 4.5, Max: 12.8
Current: 3.27
|
| PEG Ratio | 4.23 |
PEG Ratio ranked
higher than
72.87%
of
317
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 1472, Med: 1.93, Min: 0.07
GRFS:
4.23
Ranked among companies with meaningful PEG Ratio only.
|
PEG Ratio range over the past 10 years
Min: 0.54, Med: 2.39, Max: 4.68
Current: 4.23
|
| Current Ratio | 2.87 |
Current Ratio ranked
lower than
81.29%
of
855
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 413.44, Med: 2.39, Min: 0.02
GRFS:
2.87
Ranked among companies with meaningful Current Ratio only.
|
Current Ratio range over the past 10 years
Min: 1.57, Med: 2.96, Max: 3.36
Current: 2.87
|
| Quick Ratio | 1.13 |
Quick Ratio ranked
lower than
100.00%
of
855
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 413.44, Med: 1.87, Min: 0.02
GRFS:
1.13
Ranked among companies with meaningful Quick Ratio only.
|
Quick Ratio range over the past 10 years
Min: 0.71, Med: 1.4, Max: 1.88
Current: 1.13
|
| Days Inventory | 271.34 |
Days Inventory ranked
lower than
56.42%
of
755
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 950.68, Med: 119.8, Min: 0.2
GRFS:
271.34
Ranked among companies with meaningful Days Inventory only.
|
Days Inventory range over the past 10 years
Min: 235.92, Med: 271.95, Max: 909.7
Current: 271.34
|
| Days Sales Outstanding | 47.14 |
Days Sales Outstanding ranked
higher than
79.09%
of
770
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 864.61, Med: 81.76, Min: 0.1
GRFS:
47.14
Ranked among companies with meaningful Days Sales Outstanding only.
|
Days Sales Outstanding range over the past 10 years
Min: 23.54, Med: 53.12, Max: 83.07
Current: 47.14
|
| Days Payable | 81.01 |
Days Payable ranked
higher than
71.90%
of
758
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 952.38, Med: 76.32, Min: 0.04
GRFS:
81.01
Ranked among companies with meaningful Days Payable only.
|
Days Payable range over the past 10 years
Min: 64.56, Med: 81.44, Max: 256.52
Current: 81.01
|
Dividend & Buy Back
| Current | vs industry | vs history | |
|---|---|---|---|
| Dividend Yield % | 2.02 |
Trailing Dividend Yield ranked
higher than
93.09%
of
752
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 25.84, Med: 1.54, Min: 0.04
GRFS:
2.02
Ranked among companies with meaningful Trailing Dividend Yield only.
|
Trailing Dividend Yield range over the past 10 years
Min: 0.48, Med: 1.36, Max: 2.04
Current: 2.02
|
| Dividend Payout Ratio | 0.50 |
Dividend Payout Ratio ranked
higher than
94.13%
of
477
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 68, Med: 0.3, Min: 0.02
GRFS:
0.5
Ranked among companies with meaningful Dividend Payout Ratio only.
|
Dividend Payout Ratio range over the past 10 years
Min: 0.14, Med: 0.36, Max: 0.63
Current: 0.5
|
| 3-Year Dividend Growth Rate (Per Share) | 7.70 |
3-Year Dividend Growth Rate ranked
higher than
87.63%
of
299
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 114, Med: 7.4, Min: -100
GRFS:
7.7
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
|
3-Year Dividend Growth Rate range over the past 10 years
Min: 0, Med: -100, Max: 46.3
Current: 7.7
|
| Forward Dividend Yield % | 1.75 |
Forward Dividend Yield ranked
higher than
93.18%
of
719
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 25.84, Med: 1.66, Min: 0.04
GRFS:
1.75
Ranked among companies with meaningful Forward Dividend Yield only.
| N/A |
| Yield-on-Cost (5-Year) % | 6.29 |
Yield-on-Cost (5y) ranked
higher than
90.20%
of
745
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 42.46, Med: 2.12, Min: 0.03
GRFS:
6.29
Ranked among companies with meaningful Yield-on-Cost (5y) only.
|
Yield-on-Cost (5y) range over the past 10 years
Min: 1.49, Med: 4.23, Max: 6.35
Current: 6.29
|
| 3-Year Share Buyback Rate | -0.10 |
3-Year Share Buyback Rate ranked
lower than
100.00%
of
571
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 100, Med: -5.3, Min: -815
GRFS:
-0.1
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
|
3-Year Share Buyback Rate range over the past 10 years
Min: -46.1, Med: -1.5, Max: 20.3
Current: -0.1
|
Valuation & Return
| Current | vs industry | vs history | |
|---|---|---|---|
| Price-to-Projected-FCF | 2.13 |
Price-to-Intrinsic-Value-Projected-FCF ranked
higher than
78.61%
of
374
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 209, Med: 2.11, Min: 0.05
GRFS:
2.13
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
|
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 1.65, Med: 2, Max: 5.96
Current: 2.13
|
| Price-to-DCF (Earnings Based) | 1.39 |
Price-to-Intrinsic-Value-DCF (Earnings Based) ranked
higher than
89.09%
of
110
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 27.76, Med: 1.36, Min: 0.14
GRFS:
1.39
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
| N/A |
| Price-to-Median-PS-Value | 1.01 |
Price-to-Median-PS-Value ranked
lower than
75.37%
of
743
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 238.36, Med: 0.94, Min: 0.01
GRFS:
1.01
Ranked among companies with meaningful Price-to-Median-PS-Value only.
|
Price-to-Median-PS-Value range over the past 10 years
Min: 0.57, Med: 1.01, Max: 3.17
Current: 1.01
|
| Price-to-Peter-Lynch-Fair-Value | 4.61 |
Price-to-Peter-Lynch-Fair-Value ranked
lower than
100.00%
of
212
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 26.42, Med: 1.41, Min: 0.08
GRFS:
4.61
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
|
Price-to-Peter-Lynch-Fair-Value range over the past 10 years
Min: 0.95, Med: 2.45, Max: 4.63
Current: 4.61
|
| Earnings Yield (Joel Greenblatt) % | 6.52 |
Earnings Yield (Greenblatt) ranked
higher than
82.47%
of
867
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 769.23, Med: 3.31, Min: -333.33
GRFS:
6.52
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
|
Earnings Yield (Greenblatt) range over the past 10 years
Min: 2.2, Med: 5.1, Max: 7.1
Current: 6.52
|
| Forward Rate of Return (Yacktman) % | 8.57 |
Forward Rate of Return ranked
higher than
78.38%
of
421
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 559.55, Med: 8.96, Min: -1635.32
GRFS:
8.57
Ranked among companies with meaningful Forward Rate of Return only.
|
Forward Rate of Return range over the past 10 years
Min: 8.5, Med: 14.5, Max: 23
Current: 8.57
|
More Statistics
| Revenue (TTM) (Mil) $ | 5,314.55 |
| EPS (TTM) $ | 0.95 |
| Beta | 0.95 |
| Volatility % | 14.9 |
| 52-Week Range $ | 17.42 - 22.81 |
| Shares Outstanding (Mil) | 684.14 |
Analyst Estimate
Piotroski F-Score Details
| Piotroski F-Score | 4 |
| Positive ROA | Y |
| Positive CFROA | Y |
| Higher ROA yoy | N |
| CFROA > ROA | N |
| Lower Leverage yoy | Y |
| Higher Current Ratio yoy | N |
| Less Shares Outstanding yoy | N |
| Higher Gross Margin yoy | N |
| Higher Asset Turnover yoy | Y |